摘要
目的:探讨血清肿瘤标志物CEA、CA125与非小细胞肺癌(non-small cell lung cancer,NSCLC)患者EGFR突变是否具有相关性。方法:收集2010年1月-2012年7月我科收治的初治NSCLC患者共155例,用蛋白芯片-化学发光法和液相芯片技术检测NSCLC患者血清肿瘤标志物CEA、CA125的表达及与病理组织EGFR基因突变情况,分析CEA、CA125在NSCLC中表达特点及CEA、CA125的表达水平与EGFR突变率的关系。结果:治疗前血清CEA、CA125表达异常与患者EGFR敏感突变无相关性。但治疗前血清CEA、CA125表达水平高于正常10倍以上时,EGFR突变率显著升高;且随着CEA、CA125水平异常程度的升高,EGFR突变率呈上升趋势,具有统计学差异。结论:对于无法进行EGFR突变检测的NSCLC患者,治疗前血清CEA、CA125表达水平高于10倍以上者,其可能是EGFR-TKI治疗优势人群。
Objective:To explore the relation of serum tumor markers CEA and CA125 with EGFR sensitive mutation in non- small cell lung cancer(NSCLC) patients and the predictive value. Methods:A total of 155 NSCLC patients were newly diagnosed from January 2010 to July 2012 in our department. Using protein chip and chemiluminescence method and liquid chip technology to detect serum tumor markers CEA,CA125 and histopathologic EGFR gene mutation. We analyzed the expression characteristics of serum CEA and CA125 in NSCLC as well as the relationship of the two tumor markers with EGFR sensitive mutation. Results:The expression level of CEA and CA125 before treatment up to 10 times higher than normal,increased as the degree of abnormal CEA,CA125. Conclusion:EGFR mutation rate is associated with the degree of pretreatment level of serum CEA and CA125.
出处
《现代肿瘤医学》
CAS
2014年第9期2101-2105,共5页
Journal of Modern Oncology
